Table 3. Association analyses performed after excluding outliers between amygdala activation in the Negative Faces > Shapes contrast and oxytocin receptor polymorphisms.
| SNP | Amygdala hemisphere | SCZ n=97 | AD n=99 | HC n=138 | Total N=334 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Effect size | P | Effect size | P | Effect size | P | Effect size | P | ||
| Rs2254298 (G)a | Left | b=0.52 | 0.85 | b=−1.94 | 0.51 | b=1.12 | 0.60 | b=0.37 | 0.80 |
| Right | b=0.66 | 0.81 | b=3.60 | 0.24 | b=−0.13 | 0.95 | b=1.29 | 0.38 | |
| Rs53576 (G)a | Left | b=2.45 | 0.16 | b=−0.46 | 0.83 | b=−2.60 | 0.12 | b=−0.39 | 0.71 |
| Right | b=0.36 | 0.84 | b=−0.24 | 0.91 | b=−0.51 | 0.76 | b=−0.21 | 0.84 | |
| Rs237902 (G)ac | Left | b=−4.56 | 0.004b | b=−0.15 | 0.93 | b=1.93 | 0.19 | b=−0.66 | 0.48 |
| Right | b=−3.69 | 0.03 | b=−2.54 | 0.16 | b=2.09 | 0.16 | b=−1.07 | 0.25 | |
SNP, single nucleotide polymorphism; SCZ, schizophrenia spectrum disorders; AD, affective spectrum disorders; HC, healthy controls.
a
Results for the G allele dosage are displayed.
b
Remains significant after Bonferroni corrections (3 independent tests).
c
Interaction analyses in the total sample showed a significant effect of having a diagnosis of SCZ compared to healthy controls on the association between rs237902 and amygdala activation (left hemisphere; b=−6.95, P=0.002, Bonferroni corrected P=0.006, right hemisphere; b=−6.05 , P=0.009, Bonferroni corrected P=0.03), while this was not the case for patients with AD (left hemisphere; b=−2.46, P=0.26, right hemisphere; b=−4.87, P=0.03, Bonferroni corrected P=0.09).